Our Extended Family of Portfolio Companies

Investing in transformational ideas and entrepreneurial grit to solve major unmet needs in patient care

view more →

Bivarus is a healthcare IT company that has developed an elegant and efficient patient survey platform. Acquired by Press Ganey Associates in January 2018.

view more →

(BITT) is a Boston-based biopharmaceutical company developing immune-based approaches for the treatment of cancer and infectious diseases.

view more →

Developer of a technology designed to extract highly sensitive nucleic acid quantification. Acquired by Bio-Rad 2021

view more →

Provider of a clinical research platform intended to revolutionize the clinical research industry

view more →

Kymera is developing a heterobifunctional small molecule drug platform. IPO in August 2020 (NASDAQ: KYMR).

view more →

Provider of patient experience platform designed to facilitate the relationship between physicians and patients. Acquired by NextGen 2019

view more →

Developer of staffing, communication and schedule management tools designed to modernize staffing processes. Acquired by HealthStream 2020

view more →

Perfuse Therapeutics, Inc. is a seed stage biotechnology company focusing on improving retinal perfusion

view more →

Developer of a molecular diagnostics technology designed to dramatically reduce time to results in microbiology.

view more →

A developer of multiple antibiotic drugs intended to combat antimicrobial resistance. Acquired by Shionogi 2023

view more →

The SHAPE-MaP technology developed in the lab of Dr. Weeks identifies functional motifs within RNA by mapping the RNA three-dimensional structure.

view more →

Developer of epigenetic drugs intended to be used for the treatment of cognitive disorders and diseases of the brain. Acquired by NASDAQ: ALKS in Nov 2019

view more →

Standard Bariatrics is developing a clamp and stapler to standardize sleeve gastrectomy procedures. Acquired by Teleflex in September 2022.

view more →

Stridebio is developing engineered viral vectors for gene therapy. Acquired by Ginkgo Bioworks 2023

view more →

Developer of novel engineered compounds designed to corneal dystrophies, improve human health and create new therapies using drugs developed with protein engineering.

“It is not the critic who counts: not the man who points out how the strong man stumbles or where the doer of deeds could have done better. The credit belongs to the man who is actually in the arena, whose face is marred by dust and sweat and blood, who strives valiantly, who errs and comes up short again and again, because there is no effort without error or shortcoming, but who knows the great enthusiasms, the great devotions, who spends himself in a worthy cause; who, at the best, knows, in the end, the triumph of high achievement, and who, at the worst, if he fails, at least he fails while daring greatly, so that his place shall never be with those cold and timid souls who knew neither victory nor defeat.”


Theodore Roosevelt
Speech at the Sorbonne, Paris, April 23, 1910